ABSTRACT
A Sindbis virus replicon-based DNA vaccine containing VP2 gene of canine parvovirus (CPV) was delivered by Escherichia coli to elicit immune responses. The orally immunized dogs developed CPV-specific serum IgG and virus neutralizing antibody responses. The cellular immune responses analyzed using lymphocyte proliferation test and flow cytometry indicated CPV-specific sensitization of both CD3+CD4+ and CD3+CD8+ lymphocytes. This study demonstrated that the oral CPV DNA vaccine delivered by E. coli can be considered as a promising approach for vaccination of dogs against CPV.
Subject(s)
Capsid Proteins/immunology , Parvoviridae Infections/veterinary , Sindbis Virus/genetics , Vaccines, DNA/immunology , Viral Vaccines/immunology , Administration, Oral , Animals , Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Capsid Proteins/genetics , Cell Line , Dog Diseases/immunology , Dog Diseases/prevention & control , Dog Diseases/virology , Dogs , Escherichia coli/genetics , Immunization , Immunoglobulin G/blood , Lymphocyte Activation/immunology , Parvoviridae Infections/immunology , Parvoviridae Infections/prevention & control , Parvoviridae Infections/virology , Parvovirus, Canine/genetics , Parvovirus, Canine/immunology , Replicon/genetics , Vaccines, DNA/administration & dosage , Vaccines, DNA/genetics , Viral Vaccines/administration & dosage , Viral Vaccines/geneticsABSTRACT
A Sindbis virus (SINV) replicon-based DNA vaccine encoding Rabies virus (RABV) glycoprotein G developed previously (Saxena et al., Vaccine 26, 6592, 2008) was used for immunization of dogs against rabies. The intradermal injection of DNA vaccine into external ear generated protective level of virus neutralizing antibodies. The cellular immune response was specific to RABV, in particular by an increase in CD3+CD4+ and CD3+CD8+ lymphocytes. This study has demonstrated that the SINV replicon-based DNA vaccine encoding RABV G is capable of inducing the protective level of specific immune response in dogs.
Subject(s)
Antibodies, Viral/blood , Antigens, Viral/immunology , Dog Diseases/prevention & control , Glycoproteins/immunology , Rabies Vaccines , Rabies/veterinary , Replicon/genetics , Sindbis Virus/genetics , Vaccines, DNA , Viral Envelope Proteins/immunology , Animals , Antigens, Viral/genetics , CD3 Complex/metabolism , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Dog Diseases/immunology , Dogs , Glycoproteins/genetics , Immunization , Neutralization Tests , Rabies/prevention & control , Rabies/virology , Rabies Vaccines/administration & dosage , Rabies Vaccines/genetics , Rabies Vaccines/immunology , Vaccines, DNA/administration & dosage , Vaccines, DNA/genetics , Vaccines, DNA/immunology , Viral Envelope Proteins/geneticsABSTRACT
Adverse alterations in lipid profile suggesting higher atherogenicity were observed following 12 weeks treatment with atenolol in patients of hypertension. No significant alterations in lipid profile were observed with labetalol therapy.
